190 related articles for article (PubMed ID: 31972992)
21. The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.
Britten CM; Meyer RG; Frankenberg N; Huber C; Wölfel T
J Immunol Methods; 2004 Apr; 287(1-2):125-36. PubMed ID: 15099761
[TBL] [Abstract][Full Text] [Related]
22. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
Simon P; Omokoko TA; Breitkreuz A; Hebich L; Kreiter S; Attig S; Konur A; Britten CM; Paret C; Dhaene K; Türeci Ö; Sahin U
Cancer Immunol Res; 2014 Dec; 2(12):1230-44. PubMed ID: 25245536
[TBL] [Abstract][Full Text] [Related]
23. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.
Johnson LA; Heemskerk B; Powell DJ; Cohen CJ; Morgan RA; Dudley ME; Robbins PF; Rosenberg SA
J Immunol; 2006 Nov; 177(9):6548-59. PubMed ID: 17056587
[TBL] [Abstract][Full Text] [Related]
24. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells.
Koesters R; Linnebacher M; Coy JF; Germann A; Schwitalle Y; Findeisen P; von Knebel Doeberitz M
Int J Cancer; 2004 Apr; 109(3):385-92. PubMed ID: 14961577
[TBL] [Abstract][Full Text] [Related]
25. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
26. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
[TBL] [Abstract][Full Text] [Related]
27. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
28. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
29. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
Thomas S; Xue SA; Cesco-Gaspere M; San José E; Hart DP; Wong V; Debets R; Alarcon B; Morris E; Stauss HJ
J Immunol; 2007 Nov; 179(9):5803-10. PubMed ID: 17947653
[TBL] [Abstract][Full Text] [Related]
31. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.
Campillo-Davo D; Flumens D; Lion E
Cells; 2020 Jul; 9(7):. PubMed ID: 32708366
[TBL] [Abstract][Full Text] [Related]
32. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
[TBL] [Abstract][Full Text] [Related]
33. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
34. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
[TBL] [Abstract][Full Text] [Related]
35. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
[TBL] [Abstract][Full Text] [Related]
36. Specific roles of each TCR hemichain in generating functional chain-centric TCR.
Nakatsugawa M; Yamashita Y; Ochi T; Tanaka S; Chamoto K; Guo T; Butler MO; Hirano N
J Immunol; 2015 Apr; 194(7):3487-500. PubMed ID: 25710913
[TBL] [Abstract][Full Text] [Related]
37. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
38. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
39. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
40. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
Yao X; Matosevic S
Immunol Lett; 2024 May; 268():106881. PubMed ID: 38810886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
